Barinthus Bio’s VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Published on :

Barinthus Bio’s VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B OXFORD, United Kingdom, June 06, 2024 [….]

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

Published on :

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology and [….]